Precocious Puberty : Clinical and Endocrine Profile and Predictors of Neurogenic Etiology in Girls with Central Precocious Puberty by Srinivasan, P
PRECOCIOUS PUBERTY : CLINICAL AND 
ENDOCRINE PROFILE AND PREDICTORS OF 
NEUROGENIC ETIOLOGY IN GIRLS WITH 
CENTRAL PRECOCIOUS PUBERTY 
 
Dissertation submitted in partial fulfilment of the 
requirements for the degree of 
 
M.D. (PAEDIATRICS) 
BRANCH - VII 
 
INSTITUTE OF CHILD HEALTH AND HOSPITAL FOR CHILDREN, 
MADRAS MEDICAL COLLEGE, 
CHENNAI – 600 003. 
 
 
 
 
 
 
 
THE TAMIL NADU 
DR. M.G.R. MEDICAL UNIVERSITY 
APRIL 2012 
 CERTIFICATE 
 
This is to certify that the dissertation entitled, “SEXUAL 
PRECOCITY: CLINICAL AND ENDOCRINE PROFILE AND 
PREDICTORS OF NEUROGENIC ETIOLOGY IN GIRLS WITH 
CENTRAL PRECOCIOUS PUBERTY” submitted by 
DR.P.SRINIVASAN to the Faculty of Paediatrics, The Tamilnadu 
Dr.M.G.R Medical University, Chennai, in partial fulfilment of the 
requirements for the award of M.D. Degree (Paediatrics) is a bonafide 
research work carried out by him under our direct supervision and 
guidance, during the academic year 2009-2012. 
 
DEAN: 
Prof.Dr.V.KANAGASABAI,M.D.,  Dr.P.JEYACHANDRAN,M.D.,DCH., 
Dean,      Director and Superintendent 
Madras Medical College and  Institute of Child Health and 
Government General Hospital,  Hospital for Children 
Chennai – 600003.    Chennai - 600008. 
   
                                                                            
Dr. S. SUNDARI, M.D., D.C.H, 
Addl. Professor of Paediatrics 
Institute of Child Health and 
Hospital for Children 
Chennai – 600008. 
 
 DECLARATION 
 
I, DR. P.SRINIVASAN, solemnly declare that the dissertation 
titled “SEXUAL PRECOCITY: CLINICAL AND ENDOCRINE 
PROFILE AND PREDICTORS OF NEUROGENIC ETIOLOGY IN 
GIRLS WITH CENTRAL PRECOCIOUS PUBERTY” has been 
prepared by me under the expert guidance and supervision of 
Prof.Dr.S.SUNDARI, M.D, D.C.H., Additional Professor, Institute of 
child health and hospital for children, Madras Medical College, Chennai 
– 3. This is submitted to the Tamilnadu Dr. M.G.R. Medical University, 
Chennai in partial fulfilment of the rules and regulations for the award of 
M.D. Degree Examination in Paediatrics (Branch VII). 
 
 
 
Place : Chennai      (Dr. P.SRINIVASAN) 
Date : 
 
 
 
 
ACKNOWLEDGEMENT 
 
I thank with deep sense of gratitude Prof Dr.P.Jeyachandran 
M.D., D.C.H., Professor of Paediatrics, Director and Superintendent of 
Institute of Child Health and Hospital for Children, Egmore, Chennai for 
his kind support and guidance. 
I thank my unit Chief Retd Prof.R. Kandasamy M.D., D.C.H., 
for his guidance and support in doing this work. 
I thank my unit Chief  Prof.S.Sundarai,M.D.,D.C.H., and my unit 
Assistant Professors and my guide Dr.C.V.Ravisekar, M.D., D.C.H., 
D.N.B.,  Dr.S.Lakshmi, M.D., D.C.H., Dr.K.Kumarasamy, M.D., 
D.C.H.,D.N.B.,  and  Dr.Karamath MD., for their whole hearted 
support, guidance and help rendered to this work. 
I express my sincere thanks to Dr.S. Srinivasan, D.C.H, Registrar, 
Institute of Child health and Hospital for Children, for his support and 
guidance. 
I would fail on my part if I forget to thank all my patients and their 
caretakers for their co-operation, without which, this work would not 
have been possible. 
 
  
CONTENTS 
 
Sl.No.  Title      Page No. 
1.  INTRODUCTION     1 
2.  REVIEW OF LITRATURE    26 
3.  STUDY JUSTIFICATION    34  
4.  AIM AND OBJECTIVES    35 
5.  MATERIALS AND METHODS   36 
6.  OBSERVATIONS     40 
7.  DISCUSSIONS      55 
8.  CONCLUSION      62 
9.  SUMMARY      63 
BIBLIOGRAPHY  
ANNEXURE  
INTRODUCTION 
Puberty is characterized by the appearance of secondary sexual 
features and transition from the sexually immature form to the sexually 
mature form.  Precocious precocity is defined as the appearance of 
secondary sexual characteristics in an age that is less than 2-2.5 standard 
deviation below the mean age of puberty for general population (1, 2) or 
the onset of menstruation before 9.5 years in girls (3). Puberty sets in 
with activation of the hypothalamic-pituitary-gonadal (HPG axis). The 
hypothalamic-pituitary-gonadal (HPG) axis is relatively quiescent during 
childhood, under higher inhibitory influences that still remain 
incompletely understood. Any disruption to this normal inhibition of the 
HPG axis during childhood results in “gonadotropin dependent or central 
or true precocious puberty”. Abnormal secretion or exposure to sex 
steroids independent of the HPG axis results in “gonadotropin 
independent or pseudo or peripheral precocious puberty".   
True precocious puberty is always isosexual and the physical signs 
of sexual development are in keeping with the phenotypic gender of the 
child. In precocious pseudo puberty, the sex characteristics may be 
"isosexual" or "heterosexual". Precocious pseudo puberty may induce 
maturation of the hypothamic - pituitary - gonadal axis and trigger the 
onset of true sexual precocity. 
Incomplete sexual precocity or variants of pubertal developments 
refers to those disorders in which pubertal development is mild or non 
progressive resulting in premature thelarche or premature adrenarche or 
premature menarche. 
Normal pubertal development 
Pubertal development coincides with the activation and maturation 
of the HPG axis and also with the maturation of the adrenal cortex. The 
maturation of the HPG axis is responsible for testicular enlargement and 
increase in penile size in boys, and   breast development and menarche in 
girls. The increased androgen production from the adrenal cortex is 
responsible for development of pubic hair, body odour and acne. 
 Pulsatile release of gonadotropin releasing hormone (GnRH) from 
the hypothalamus marks the onset of puberty. GnRH release is regulated 
by the hypothalamic peptide hormone kisspeptin and its receptor GPR54 
(a G protein coupled receptor 54) (3). The expression of KISS-1 mRNA 
and GPR54 receptor correlates with the onset of puberty. The 
identification of activating GPR54 mutation as a cause of precocious 
puberty has strengthened the role of kisspeptin in pubertal regulation (4). 
GnRH stimulates the anterior pituitary to secrete luteinising hormone 
(LH) and follicle stimulating hormone (FSH). LH and FSH enter the 
systemic circulation and stimulate the ovaries and testes to produce 
estrogen and testosterone respectively. These sex steroids exert a complex 
feedback on GnRH and gonadotropin release. 
Maturation of the adrenal cortex (adrenarche) leads to production 
of increased adrenal androgens which are responsible for many of the 
secondary sexual characteristics like pubic hair (pubarche), body odour 
and acne. Adrenarche is a gradual process and may precede central 
puberty. 
 Physical changes occurring during puberty (secondary sexual 
characteristics) are a result of GnRH – driven sex steroids (estrogen and 
testosterone) and the adrenal androgens. The first sign of central puberty 
in boys is testicular enlargement (4ml) and in girls is breast development. 
Pubic hair may precede breast development in many girls. The sequence 
of progression of sexual development in both boys and girls has been well 
described by Tanner staging or sexual maturity staging (SMR) (5, 6). The 
growth spurt occurring during puberty is the result of increased sex 
hormones and growth hormone secretion. In boys the peak growth 
velocity occurs in midpuberty, whereas in girls it occurs with the onset of 
puberty.  Maturation of the epiphyseal plates and accrual of bone mineral 
density also occurs during puberty and is dependent on estrogen. 
 Timing of puberty is dependent on genetic, psychosocial and 
environmental factors. Many studies have demonstrated that black girls 
enter puberty earlier than white girls (7). Environmental factors like 
nutrition also play a role in the timing of puberty, with obese girls 
entering puberty much earlier (8). 
 The standards for pubertal timing as demonstrated by observational 
studies by Tanner and Marshall (5, 6) were between 9.5 years and 13 
years with mean of 11.6 years in males as evidenced by enlargement of 
testes. In females the age of pubertal onset was between 8.5 – 13 years 
with mean age of 11.2 years as evidenced by breast enlargement.  
Hormonal changes in puberty: 
Sex hormone levels are high at birth and remain so during infancy 
due to high gonadotropin levels (minipuberty).high estrogen levels in 
girls at birth reflect transplacental transfer of maternal estrogen. This may 
result in transient breast enlargement, galactorrhea and withdrawal 
vaginal bleeding. Minipuberty is more marked in boys and may last upto 
one year of life (9). Beyond infancy, gonadotropin levels become 
undetectable till the onset of puberty. However; the prepubertal phase is 
not quiescent and is characterized by episodic secretion of gonadotropin. 
Baseline FSH levels are higher compared to LH in Prepubertal girls and 
may overlap with those observed in pubertal girls. Increased GnRH 
secretion is the first identifiable event of puberty. This is related to the 
increased production of hypothalamic kisspeptin in response to central 
(neurotransmitters) and peripheral signals (leptin and ghrelin).during the 
initial phases of puberty, GnRH pulses occur during night followed by 
pulses during both day and night. This results in increase in the LH levels 
as much as 25 times during puberty as compared to FSH, which increases 
only 2.5 fold (9). LH levels are, therefore better indicators of pubertal 
status compared to FSH levels. The pulsatile pattern disappears after 
completion of pubertal changes.  
Pubertal development in girls: 
Enlargement of breast (thelarche) is the first pubertal event in girls 
closely followed by the development of pubic hair (pubarche) and onset 
of menstrual cycles (menarche). Breast development may remain 
unilateral initially or may be asymmetrical to begin with during the first 
year of thelarche. Although pubarche occurs within six months of 
thelarche it may precede thelarche in 10% girls (9). Menarche is usually 
attained within two years of thelarche; menstrual cycles are usually 
anovulatory during the first year. 
Puberty is associated with increase in vaginal length and 
appearance of estrogenic changes in the vaginal mucosa. Inspection of 
vaginal mucosa helps in assessing the pubertal status of a girl. Red 
glistening vaginal mucosa suggests lack of estrogen exposure and 
prepubertal state, while pink mucosa with mucus production is indicative 
of pubertal state and estrogenic effect. The first radiologically identifiable 
change of puberty is the increase in the ratio of uterine fundus to cervix, 
resulting in change in the shape of uterus from a tubular structure to a 
pear shaped one (9). This is followed by increase in uterine length and 
endometrial thickness. Endometrial thickness greater than 5mm suggests 
imminent menarche. Puberty is associated with increase in ovarian 
volume and development of multiple ovarian follicles giving the 
appearance of multicystic ovary. It can be readily differentiated from 
polycystic ovarian syndrome (PCOS) by the presence of small (<8 mm) 
and centrally located cysts. 
Estrogen accelerates growth by direct effect on the growth plate 
and indirect effect on the GH-IGF-1 axis. This results in a pubertal 
growth spurt with a peak growth velocity of 8-10 cm an year during the 
first half of puberty (Tanner stage I and II).the extent of growth after 
puberty may be influenced by the timing of menarche. While most girls 
grow by 4-6cm after menarche, postmenarchal growth might be 10 cm in 
girls with early menarche (9). Puberty is associated with change in the 
amount (increase) and distribution of adipose tissue (feminine 
distribution).attainment of peak bone mass closely follows peak height 
velocity and usually occurs by 16 years of age. 
The progression of puberty in girls is graded according to Tanner 
staging, which takes breast and pubic hair development into 
consideration. 
MARSHALL  WA  AND  TANNER  JM  STAGES  OF  PUBERTAL  
DEVELOPMENT  IN GIRLS (6). 
BREAST DEVELOPMENT 
Stage:   Characteristics 
I  Prepubertal; elevation of the papilla only 
II  Breast buds are noted or palpable; enlargement of the areola 
III Further enlargement of the breast and areola, with no 
separation of their contours. 
IV Projection of areola and papilla to form a secondary mound             
above the level of the breast. 
V Adult contour breast with projection of papilla only. 
PUBIC HAIR DEVELOPMENT 
Stage:   Characteristics 
I  Prepubertal; no pubic hair 
II Sparse growth of long, straight or slightly curly, minimally 
pigmented hair, mainly on the labia. 
III Considerably darker and coarser hair spreading over the  
mons pubis. 
IV Thick, adult type hair that does not yet spread to the               
medial surface of thighs 
V Hair adult in type and distributed in the classic inverse               
triangle. 
Pattern of Pubertal Development in Boys 
The physical characteristics of the stages of genital and pubic hair 
development in boys are primarily the result of androgen secretion by the 
testes. Adrenal androgens may account for some pubic hair development 
or, in rare cases, even phallic growth. Boys normally enter puberty 
between the ages of 9 and 14 years (5). Pubertal development in about 
98% of normal boys begins with testicular enlargement and is followed 
within 6 months by the appearance of pubic hair. Boys complete puberty 
in 2 - 4.5 years (5). Phallic enlargement usually occurs 12 to 18 months 
after testicular enlargement. The development of axillary and facial hair 
is highly variable. Axillary hair usually appears 2 years after pubic hair, 
in stage IV, and facial hairs simultaneously with or slightly after axillary 
hair. 
Pubertal growth spurt in boys occurs later than in girls (Tanner 
stage III and IV) and is associated with higher peak growth velocity (10-
12 cm/year).puberty is associated with decrease in body fat and increase 
in lean body mass and muscle mass. Boys tend to accrue bone mineral 
content till the age of 18 years. 
Pubertal development in boys is staged according to Tanner’s 
method. 
    
MARSHALL WA, TANNER JM STAGES OF PUBERTAL 
DEVELOPMENT IN BOYS (5). 
GENITAL DEVELOPMENT 
Stage         Characteristics 
I  Prepubertal; testicular length < 2.5 cm or volume 1-3 mL 
II Testes > 2.5 cm in the longest diameter or volume 4-8 mL; 
early penile growth and scrotal growth; scrotal skin is thin, 
red and rugose 
III testes enlarge (length 3.3-4 cm; volume 10-15 mL); 
increased penile length and width; and scrotal growth 
IV Penis further enlarged; testes length4-4.5 cm or volume 15-
20 mL, with darker scrotal skin color. 
V Genitalia adult in size and shape. Testes >4.5 cm or volume 
25 mL 
PUBIC HAIR DEVELOPMENT 
Stage :             Characteristics 
I   Prepubertal, no pubic hair 
II Sparse growth of slightly pigmented, slightly curly pubic 
hair, mainly at the base of the penis.                    
III Thicker, Curlier hair, spread to the mons pubis 
IV Adult type hair that does not yet spread to the medial thighs 
V Adult type hair spread to the medial thighs 
Variations of normal pubertal development: 
          Variations of normal pubertal development like premature 
thelarche and premature adrenarche can occur in otherwise healthy 
children and may mimic precocious puberty. These conditions do not 
require any treatment other than reassurance and follow-up every 3 – 6 
months. However, it is important to distinguish these conditions from 
pathological precocious puberty. 
Premature thelarche: 
Premature thelarche is characterized by isolated breast enlargement 
in girls younger than 8 years of age. This condition is self-limited and is 
not associated with height acceleration or advancement of bone age. 
Premature thelarche may be unilateral or bilateral and regression may 
happen when it occurs in girls less than 2 years of age. There may be a 
mild rise in estradiol levels. GnRH stimulation test demonstrates an 
increased FSH response with prepubertal LH response. This condition 
requires no treatment, but mandates close follow-up to ensure that there is 
no rapid progression to CPP (10). 
Premature adrenarche: 
Girls are more frequently affected than boys and the benign form 
of premature adrenarche should be differentiated from pathological 
forms. With benign premature adrenarche the bone age advancement is < 
2 years from the chronological age or equivalent to the height age. Serum 
dehydroepiandrosteronesulfate (DHEAS) and testosterone levels may be 
elevated for age, but are appropriate for the Tanner stage of pubic hair 
development (11). There will be no signs of gonadal maturation in boys 
or girls. The presence of clitoral hypertrophy or hirsuitism in girls 
suggests pathological adrenarche. No treatment is necessary for the 
benign form of premature adrenarche, but close follow-up for abnormal 
pubertal progression is important. Girls with premature adrenarche have 
an increased risk for hyperinsulinism and ovarian hyperandrogenism later 
in life. 
Precocious puberty 
 Precocious puberty is defined as the onset of puberty at a younger 
age than expected for normal population. Based on Tanner’s and 
Marshal’s observational studies (5, 6), pubertal signs occurring prior to 8 
years in girls and prior to 9 years in boys are considered precocious. 
Recent data however have shown a secular trend in the timing of puberty 
with many girls attaining puberty earlier (12) and thereby opening a 
debate as to whether the age of onset of normal puberty should be 
reduced to 7 years in girls. 
Central precocious puberty: 
Children with central precocious puberty (CPP) exhibit isosexual 
pubertal development at an early age due to premature activation of the 
HPG axis. The pubertal stages in CPP are similar to normal puberty but 
may progress more rapidly.  Idiopathic CPP is more common in girls (13) 
whereas boys with CPP are more likely to have underlying central 
nervous system (CNS) lesion.CNS mass lesions or malformations are a 
common cause of CPP (14) especially in boys. Risk factors for a CNS 
lesion include a younger age and male gender.  
 In girls, breast development and estrogenisation of vaginal mucosa 
are the first signs of puberty. Pubarche happens next and if untreated is 
followed by menarche. Boys have testicular enlargement followed by 
increased penile size, pubarche, increased muscle mass and deepening of 
voice. Along with pubertal progression, growth acceleration with 
significant advancement of bone age occurs. Neurological symptoms like 
headache, visual disturbances and seizures raise the suspicion of a CNS 
lesion. Gelastic seizures, which manifest as laughing spells, are 
characteristic of hypothalamic hamartomas.  
Conditions causing GnRH dependent (central or true) precocity (15): 
A. Constitutional 
B. Idiopathic true precocious puberty 
C. CNS tumors 
 1.        Hamartomas of the tuber cinereum 
 2.        Other hypothalamic tumors 
           a.       Glioma 
           b.       Astrocytoma 
           c.       Ependymomas 
D.         Other CNS disorders 
                        1. Meningitis 
                        2.  Encephalitis 
                        3. Granulomas 
                        4. Brain abscesses 
                        5.          Suprasellar cysts 
                        6.          Hydrocephalus 
                        7.          Head trauma 
E. Severe Hypothyroidism 
F. True precocious puberty after late treatment of congenital virilizing 
 adrenal hyperplasia or other previous chronic exposure to sex 
 steroid. 
Peripheral precocious puberty: 
Peripheral precocious puberty (PPP) is less common than CPP. It 
occurs independent of the HPG axis maturation. The HPG axis in 
peripheral precocious puberty is suppressed by abnormally elevated 
androgens or estrogens. These sex steroids may originate from the 
adrenal glands, gonads, other organs or an exogenous source. Estrogen 
excess induces isosexual precocious puberty in girls and heterosexual 
puberty in boys; similarly increased androgens induce isosexual 
precocious puberty in boys and heterosexual puberty in girls. 
 Peripheral precocious puberty has many different causes. It can be 
due to external factors like therapeutic or accidental excess of androgens 
or estrogens.  Other causes include sex hormone secreting tumors of the 
gonads, CNS, adrenals, liver or other organs, defects in steroid 
biosynthesis or activating mutations of the LH receptors.  
Causes of GnRH independent (peripheral or pseudo) precocity (15): 
A. McCune - Albright Syndrome (polyostotic fibrous dysplasia) 
B. Males (Isosexual) 
             1.     HCG Secreting tumors 
a. CNS tumors (germinoma, chorioepithelioma 
teratoma) 
b.      Hepatoma or hepatoblastoma 
             2. Excessive androgen Secretion 
                      a.     Congenital adrenal hyperplasia 
                      b. Virilizing adrenal neoplasm 
                      c. Leydig cell tumor 
                      d. Familial gonadotropin independent Leydig cell 
maturation 
C. Males (heterosexual) 
              1. Adrenal neoplasm (Feminizing) 
              2. Increased extra glandular conversion of circulating steroids 
to estrogen 
D. Females (Isosexual) 
1.  Follicular cysts 
 2. Ovarian tumor 
                a. Granulosa cell tumor 
                 b. Lipoid tumors 
                 c. Cystadenomas 
                 d. Ovarian carcinomas  
                 e. Gonadoblastoma 
3. Adrenal tumor 
4. Exogenous estrogen 
E. Females (Heterosexual) 
1. Congenital adrenal hyperplasia 
2. Virilizing adrenal neoplasms 
3. Virilizing ovarian neoplasms 
Diagnostic evaluation of precocious puberty 
The diagnostic evaluation of all patients with precocious puberty 
should begin with a proper and thorough history. The history of age of 
onset of puberty in other family members is important. History of 
accidental or iatrogenic exposure to sex steroids should be enquired. 
History of CNS trauma, infection, presence of neurological symptoms or 
hypothyroid symptoms will also provide important clues to the diagnosis.  
 A thorough physical examination should include careful 
measurement of height, weight, assessment of body proportions and   
pubertal staging by Tanner or SMR staging. Any evidence of accelerated 
growth or growth spurt should be recorded. Other secondary sexual 
features like acne, breaking of voice and body proportions have to be 
noted. A complete neurological examination including fundoscopy and 
visual field defects should be done.  The physical examination should 
include signs for specific causes of precocious puberty such as café-au-
lait patches or bony lesions of fibrous dysplasia which are commonly 
seen in McCune Albright syndrome and neurofibromatosis. Any clinical 
findings suggestive of hypothyroidism or a palpable thyroid may give a 
clue to the etiology. 
 Investigations should be planned based on the probable diagnosis 
after the history and physical examination. Unnecessary investigations 
should be avoided if features of precocious puberty are inconsistent or not 
clearly evident and the patient must be reviewed after a few months for 
reassessment.  A skeletal age assessment is mandatory. The skeletal age 
in patients with precocious puberty is significantly advanced (> 2 yrs) 
than their chronological age. The skeletal age can also be used to predict 
adult height; predicted adult height is an important factor to be considered 
when planning treatment of precocious puberty. 
            Initial blood tests should include LH, FSH, and estradiol in girls 
and testosterone in males. Levels of sex steroid measurements must be 
done in the morning. DHEAS should be done whenever the patient 
presents with premature adrenarche.  Elevated serum levels of sex 
steroids (testosterone and estradiol) confirm the diagnosis of precocious 
puberty but do not differentiate the cause. In girls, estradiol levels are 
highly variable and have a low sensitivity for diagnosing precocious 
puberty. Elevated LH and FSH levels point towards CPP.  A  GnRH 
stimulation test is very valuable in differentiating CPP from PPP.  Peak 
LH values are used to differentiate pubertal activity of the HPG axis from 
prepubertal stage. Pre pubertal patients or those with peripheral 
precocious puberty have little or no response to GnRH stimulation (16). 
In boys with prepubertal LH levels, imaging for adrenals and estimation 
of 17 hydroxyprogesterone (17-OHP) and 11 deoxycortisol (11-OHDOC) 
should be done. Blood HCG (human chorionic gonadotropin) levels 
should be estimated if these investigations are non contributory. 
Testotoxicosis should be considered in boys presenting with peripheral 
precocity at an early age after exclusion of adrenal pathology or HCG 
secreting tumour.  
 Pelvic sonography is a very useful tool in girls to determine the 
uterine size, uterine corpus: cervix ratio and ovarian size. Tubular uterus 
with no visible endometrial stripe is suggestive of pre-pubertal state, 
while pubertal state is characterized by pear shaped structure and 
endometrial thickness greater than 3mm. The uterus and ovaries are 
appropriately enlarged in CPP (17). Unilateral enlargement of ovaries 
may indicate a cyst or tumour as in PPP. 
The main aim of evaluation of gonadotropin-dependent precocious 
puberty is the identification of an underlying organic etiology. High 
resolution magnetic resonance imaging (MRI) of the hypothalamic-
pituitary region is desirable; however, computerized tomography scan 
may be considered if MRI is not feasible. MRI of the pituitary – 
hypothalamic region is indicated in all boys and in girls less than 6 years 
of age with CPP to exclude a CNS lesion (18). MRI may be avoided in 
girls with CPP between 6-8 years as the etiology is most often idiopathic 
CPP. If there are clinical features to suggest an underlying CNS lesion, a 
MRI scan of the brain should be considered in this age group also. 
The diagnostic criteria used for classification according to etiology 
are presented in (Table 1). 
Table 1  :  Criteria for diagnosis of central and peripheral precocity 
No Diagnosis Criteria 
1. Precocious puberty 
Secondary sexual characteristics 
Boys < 9 years 
Girls< 8 years 
2. Central precocious puberty 
High estradiol or testosterone. 
Precocious puberty 
LH: FSH pubertal 
LH: FSH >1 
GnRH stimulated LH: FSH >1 
3. 
Neurogenic central 
precocious puberty 
CPP 
Known neurological disease 
Abnormal CT or MRI 
4. 
Idiopathic central precocious 
puberty 
CPP 
Normal Neuroimaging 
5. 
Peripheral precocious 
puberty 
Precocious puberty 
LH, FSH Prepubertal 
LH: FSH <1 
GnRH stimulated LH: FSH<1 
6. Premature Adrenarche 
Pubarche 
No other secondary sexual 
features 
LH, FSH prepubertal 
DHEA elevated 
No Diagnosis Criteria 
7. Premature thelarche 
Breast enlargement 
No other secondary sexual 
features 
LH, FSH normal 
8. CAH 
Premature pubarche/ virilisation 
Gonads remain prepubertal 
Elevated 17-OHP, DHEAS, 
11deoxycortisol. 
Hyperplastic adrenals on 
imaging. 
9. McCune-Albright syndrome 
Irregular café-au-lait spots, 
polyostotic fibrous dsysplasia 
Elevated estradiol. 
Multicystic ovaries on USG 
pelvis 
Low basal LH & prepubertal 
response to GnRH stimulation. 
10. 
Male-limited precocious 
puberty. 
(Testotoxicosis) 
Virilisation in early childhood. 
Large testes. 
Elevated testosterone. 
Pre-pubertal response to GnRH 
stimulation. 
 
Management: 
Suppression of puberty with GnRH analogues should be 
considered for CPP when there is significant advancement of skeletal age 
and at younger age groups as they are at risk of adult short stature due to 
premature epiphyseal fusion. Girls in the age group 6-8 years with slowly 
progressive CPP or unsustained CPP may not require treatment, but 
GnRH analogs should be considered in the presence of advanced skeletal 
maturation (height standard deviation score for bone age less than -2) and 
compromised final height (predicted height below the target height range) 
(19).  
Behavioral problems and psychological stress are also indications 
for suppression of puberty. 
Medical treatment consists of administering drugs which would 
effectively block gonadotropin release, or interfere with sex steroid 
synthesis at the gonadal level, or interfere with enzymatic action. Long 
acting GnRH agonist analogues besides inhibiting gonadotropin release 
have the additional advantage of inhibiting rapid skeletal maturation and 
linear growth, which remains unaffected by other forms of therapy. Short-
acting GnRH analogues reverse pubertal changes but do not improve 
auxological outcome. Medroxyprogesterone acetate (MPA) and 
cyproterone which interfere with sex steroid synthesis, has no beneficial 
effect on height outcome. Aromatase inhibitor included in the latter 
category prevents conversion of testosterone to estrogen or blocks the 
receptors for testosterone and dihydrotestosterone. Long acting GnRH 
analogues have become the mainstay of treatment in CPP. In general, 
GnRH analogue therapy has been more successful in boys with CPP. 
Discontinuation of treatment: 
GnRH analog should be continued till the age of 10 years in girls 
and 12 years in boys (20). Discontinuation of treatment results in gradual 
reappearance of secondary sexual characters. Menarche is usually 
attained around 12-18 months following discontinuation of treatment. 
Treatment of peripheral precocious puberty: 
Treatment of peripheral precocious puberty should be directed 
towards correction of the underlying cause (hypothyroidism, ovarian or 
adrenal tumour). GnRH analogue therapy is ineffective, and the treatment 
is instead focused on directly inhibiting the synthesis or action of sex 
steroids. Girls with McCune Albright syndrome are treated with drugs 
that inhibit the synthesis of estrogen (aromatase inhibitors) such as 
testolactone. Third generation aromatase inhibitors such as letrozole and 
anastrozole have been increasingly used.  
Most ovarian cysts regress spontaneously and do not require 
surgical intervention. Patients with complex ovarian cysts (size greater 
than 8 cm or multiseptate cysts) should undergo estimation of tumour 
markers (beta-HCG and alpha- fetoprotein) and laparotomy. Thyroid 
functions should be assessed in all girls with ovarian cysts before 
performing extensive investigation and surgery (21). 
Physiological glucocorticoid therapy is ineffective in retarding the 
pubertal progress in boys with congenital adrenal hyperplasia. Diagnosis 
is often delayed in most patients, resulting in gonadotropin-dependent 
precocious puberty. These children should be treated with GnRH analogs. 
In testotoxicosis, combination of anastrozole and anti-androgen 
biclutamide has shown to be effective (22). 
No treatment is required for normal puberty variants like premature 
thelarche or premature adrenarche. Reassurance and close follow-up to 
exclude rapid progression to CPP is all that is required for these patients. 
Predictors for neurogenic central precocious puberty: 
Clinicians who deal with CPP have two main concerns: detection 
of CNS abnormalities and short final height. The risk for girls with CPP 
to reach a final height that is too short has been widely debated, and 
several authors have suggested limiting the use of gonadotropin-releasing 
hormone analog. Thus, a means of identifying the group of girls who 
have CPP and are at high risk of CNS abnormalities is essential. In 
hospital-based studies, CPP revealed CNS abnormalities in 8% to 33% of 
the girls (23-32). Reported predictors for CNS abnormalities in girls with 
CPP are young age at the onset of puberty (35, 36, 37) presence of pubic 
hair at the same time (35) markedly advanced bone age (36, 37) rapid 
progression of puberty (36, 37) and high plasma gonadotrophins 
concentrations (35). Unfortunately, those studies were based on small 
series with high frequencies of CNS abnormalities suggestive of selection 
bias (35, 36) or did not include appropriate statistical analysis (37). New 
recommendations from the Lawson Wilkins Pediatric Endocrine Society 
(LWPES) (12) and Elders et al (38) were proposed to identify girls who 
are at high risk (for both CNS abnormalities and short final height), but 
they were mainly based on a study in which the cause of precocious 
puberty was not assessed. 
Importance of evaluation of children with precocious puberty 
1. Identifying children with pathological forms of precocious 
puberty and differentiating normal variants of pubertal development from 
the pathological forms. 
2. Determining whether the etiology is central (GnRH 
dependent) or peripheral (GnRH independent). This is crucial to planning 
appropriate investigations and therapy. 
3. The physical growth, body preoccupation and sexual interest 
correlate with sexual maturity, whereas cognitive advancement, changes 
in social behavior may correlate more closely with chronologic age. 
Discordance between chronologic age and sexual maturation increases 
the stress of adolescence. 
4. Early maturing boys enjoy higher self esteem and may seek 
older companies. They tend to enjoy greater social success. In girls early 
maturation is associated with poor school performance and lower self 
esteem. 
5. The age of onset of puberty is significant for subsequent 
growth and final height. Thus with early maturity, child has a paradox of 
tall stature in childhood but short adult height. 
6. The early maturing child often has questions about the 
somatic and sexual changes they are experiencing which places 
significant stress on the family. 
7. Sexual abuse of the early maturing child. 
REVIEW OF LITERATURE 
1. Meena Desai et al.,(23) from Wadia hospital for children, 
Bombay studied eighty children (58 girls and 22 boys) with sexual 
precocity were evaluated clinically and investigated to identify the 
underlying cause. The mean age of presentation was 4.5 years and the 
mean age of onset of symptoms was 3.37 years. 72.5% (58) of the girls 
were classified into five groups : ( i) central precocious puberty 50% (29), 
of which 52% (15) had idiopathic precocious puberty and 48% (14) had 
neurogenic precocious puberty, (ii) 35% (20) had premature thelarche, 
(iii) 9% (5) had premature adrenarche, (iv).3.5% (2) had premature 
menarche and (v) others - Hypothyroidism and McCune Albright 
syndrome constituted one each. Amongst the 22 boys (27.5%), 50% (11) 
had central precocious puberty, idiopathic in 27% (3) and neurogenic in 
73% (8). The adrenal cause constituted 32% (7), of which 86% (6) were 
congenital adrenal hyperplasia and 14% (1) were adrenocortical 
carcinoma. The testicular cause constituted 9% (2). Hypothyroidism and 
premature adrenarche constituted one each. 
2. Kandhekar et al., (24) from PGI Chandigarh studied a total 
of 31 children of which 74.2% (23) were girls and 25.8% (8) were males. 
56.5% (13) of the 23 girls had central precocious puberty, of which 85% 
(11) had idiopathic precocious puberty. Hydrocephalus and 
hypothyroidism constituted one each. 21.7% (5) had premature 
adrenarche and 21.7% (5) had premature thelarche. Out of the 5 
premature adrenarche, 60% (3) had congenital adrenal hyperplasia. 
75% (6) of the 8 boys had central precocious puberty, of which 
66.66% (4) had idiopathic precocious puberty, while hydrocephalus and 
suprasellar cyst contributed one each. 25% (2) had peripheral precocious 
puberty contributed by adrenocortical adenoma and virilizing 
hepatoblastorna. 
3. K.M.Prasanna Kumar et al.,
 
(25) from AIIMS, New Delhi 
studied Fifteen children (8 boys and 7 girls) with sexual precocity were 
evaluated. The mean age of onset was 3.5 years in boys and 4.8 years in 
girls. All the children had growth spurt and most of them were more than 
2SD above the mean, for their respective age and sex. 86% (6) of the 7 
girls had central precocious puberty, 71.5% (5) contributed by idiopathic 
precocious puberty and 14.5% (1) contributed by neurogenic cause and 
14.5% (1) were premature thelarche. 50% (4) of the boys had central 
precocious puberty, of which 25% (2) were idiopathic precocious 
puberty. Hypothalamic hamartoma and hydrocephalus contributed one 
each. Peripheral cause of precocity was found in 50% (4), all the 4 being 
congenital adrenal hyperplasia. 
4. Chemaitilly et al., (26) studied the clinical and laboratory 
features of 256 patients (26 boys and 230 girls) with CPP. He compared 
patients with idiopathic CPP (seven boys and 186 girls) to those with 
organic CPP, whose pubertal development revealed a central nervous 
system (CNS) lesion (five boys and 11 girls), and to patients with organic 
CPP associated with a previously treated CNS lesion  (14 boys and 33 
girls). Boys with organic CPP, having revealed or treated CNS lesions, 
started their puberty earlier (3.0 +/- 1.0 years and 6.7 +/- 0.5 years) than 
boys with idiopathic CPP (8.5 +/- 0.2 years, P < 0.01 and < 0.05). Boys 
with organic CPP associated with a treated CNS lesion had lower 
luteinizing hormone (LH)/follicle stimulating hormone (FSH) peaks ratio 
after stimulation with gonadotrophin releasing hormone (GnRH) (1.6 +/- 
0.5) than did boys with idiopathic CPP (2.2 +/- 0.3, P < 0.05). Girls with 
organic CPP revealing a CNS lesion started their puberty earlier (3.6 +/- 
0.9 years) than girls with idiopathic CPP (6.6 +/- 0.1 years, P < 0.0 l) and 
had higher LH (P < 0.01) and FSH peaks (< 0.05). Girls with organic 
CPP associated with a treated CNS lesion had higher BMI (1.8 +/- 0.2 z-
score) than did girls with idiopathic CPP (1.3 +/- 0.1 zs, P < 0.05), higher 
leptin concentrations (11.7 +/- 1.8 microg/l vs. 7.7 +/- 0.5 microg/l, P < 
0.0 l), LH peak (P < 0.01), FSH peak (P < 0.05) and LH/FSH peaks ratio 
(1 +/- 0.1 vs. 0.8 +/- 0.1, P < 0.05). Only 12.4% of the girls with 
idiopathic CPP had BMI-zs < 0, and their plasma leptins were positively 
correlated with BMI (P < 0.0001). 
5. Kaplan SL et al.,
 
(27) from University of California, 
Sanfrancisco studied a total 205 children with true precocious puberty 
and evaluated them to find out the etiology. 81% (166) were female 
children, out of which 59% (121) had idiopathic precocious puberty and 
22% (45) had neurogenic cause. 9% (39) were boys, out of which 6.34% 
(13) had idiopathic precocious puberty and 12.68% (26) neurogenic. 
6. Paul Kaplowitz (28) from Department of Endocrinology, 
Children’s National Medical Center, Washington, D.C. reviewed data of 
104 children referred for signs of early puberty. Criteria were developed 
to assign patients to one of seven diagnostic categories based on age, 
growth, and clinical findings and differences from the population mean 
for height and percentage of ideal body weight in the different groups 
were determined. Most of the patients referred (87%) were female, and 
the two most common diagnoses made were premature adrenarche (46%) 
and premature thelarche (18%). Only 9% (all girls) were thought to have 
true precocious puberty. Two conditions not well described in the 
literature, pubic hair of infancy and premature menses, were found in 8% 
and 5%, respectively. Patients with premature adrenarche were 
significantly taller and more overweight than the general population; a 
subgroup had evidence of accelerated growth and bone maturation but no 
worrisome endocrine findings. Acanthosis nigricans was found in 13% of 
the girls in this study, but the incidence of true endocrine pathology was 
very low. The majority of children being referred for precocious puberty 
have benign normal variants, with a very low incidence of endocrine 
pathology. Most girls presenting with minimal breast or pubic hair 
development and normal growth velocity may be managed with 
observation and without a full endocrine evaluation. 
7. Rohani et al., (29) from Endocrine Research Centre, 
Institute of Endocrinology and Metabolism (Hemmat Campus), in their 
case series study evaluated, 44 girls and 8 boys with precocious puberty 
in a 10 years period of time.  
Mean age of girls and boys was 7.43±1.4 years and 5.8±2.1 years 
respectively. Most of the patients fell within the age category of 7-7.9 
years old (40.9% for girls and 50% for boys). Patients, concerning 
etiology of precocious puberty were classified in three categories: 42.6% 
of patients had central precocious puberty (CPP), including idiopathic 
CPP (87.5%) and neurogenic CPP (12.5%). 23.3% of patients had 
peripheral precocious puberty (PPP), including congenital adrenal 
hyperplasia (CAH) (42.8%), ovarian cysts (28.4%), McCune-Albright 
syndrome (14.2%) and adrenal carcinoma (14.2%). 34.1% of girls and 
25% of boys had normal variant puberty including premature thelarche 
(57%), premature adrenarche (38%) as well as premature menarche 
(4.7%).  
The most common etiology of precocious puberty in girls was 
idiopathic central precocious puberty and premature thelarche, while in 
boys they were neurogenic central precocious puberty and CAH. 
Therefore precocious puberty in girls is usually benign. In boys, CNS 
anomalies should first be considered in the differential diagnosis of CPP. 
Therefore brain Magnetic Resonance Imaging (MRI) is mandatory in all 
cases. 
8. A. Bajpai et al., (30) from All India Institute of Medical 
Sciences, New Delhi, India evaluated records of 140 patients (114 girls, 
26 boys) with precocious puberty. Girls outnumbered boys in this series 
(4.4:1). Neurogenic central isosexual precocious puberty (CIPP) was 
more common in boys (10out of 18, 55.6%) than girls (16 out of 77, 
20.8%). The most common cause of neurogenic CIPP was hypothalamic 
hamartoma present in five girls and four boys. Other causes of neurogenic 
CIPP included neurotuberculosis, pituitary adenoma, hydrocephalus, post 
radiotherapy, CNS tumors and malformations. Peripheral precocious 
puberty (PPP) was secondary to adrenal causes in boys and ovarian cysts 
in girls. Benign variants of precocious puberty, such as premature 
thelarche and premature adrenarche, were present in 23 and six girls, 
respectively. Hypothyroidism was present in four girls and McCune-
Albright syndrome in one girl. Girls with neurogenic CIPP had a lower 
age of onset as compared to idiopathic CIPP (3.6 ± 2.7 years vs 5.4 ± 2.5 
years, (ρ = 0.014). The lowest age of onset was seen in girls with 
hypothalamic hamartoma (1.6 ± 0.9 years). Forty-seven girls with CIPP 
(seven neurogenic and 40 idiopathic) presented after the age of 6 years. 
Features of CNS involvement, in the form of seizures, mental retardation, 
raised intracranial tension or focal neurological deficits were present in 
seven girls (43.8%) and four boys (40%), and gelastic seizures were 
present in three children. Girls with CIPP had greater bone age 
advancement (3.4 ± 1.5 years) and negative height standard deviation for 
bone age (-2.7 ± 1.5) than those with PPP (1.9 ± 1.6 years and -1.3 ± 1.3) 
and premature thelarche  (0.4 ± 0.4 years and -0.8 ± 0.8). Patients with 
neurogenic CIPP had significantly higher levels of baseline and 
GnRHstimulated levels of LH and FSH and LH: FSH ratio than those 
with idiopathic CIPP. Occurrence of neurogenic CIPP in seven girls with 
an age of onset after 6 years emphasizes the need for CNS imaging in 
these girls contrary to the current recommendations. The fact that 65.6% 
cases of idiopathic CIPP presented after the age of 6 years raises the 
possibility that these patients may be physiological variants of normal 
puberty. Pointers to neurogenic CIPP included early age of onset in girls, 
clinical features of CNS involvement, and elevated basal and stimulated 
LH levels and LH: FSH ratio. 
9. Martin Chalumeau et al., (31) from university pediatric 
hospital in Paris, France conducted a retrospective cohort study of all 
girls younger than 8 years with breast development related to CPP, seen 
between 1982 and 2000. For a pilot population (186 idiopathic, 11 
revealing CNS abnormalities), the accuracy of the Lawson Wilkins 
Pediatric Endocrine Society recommendations were evaluated. Potential 
clinical, radiological, and biological predictors of CNS abnormalities 
were assessed by univariate and multivariate analyses. Applying the 
Lawson Wilkins Pediatric Endocrine Society recommendations, 2 of 11 
girls with CPP that revealed CNS abnormalities would not have been 
considered to require brain imaging. Independent predictors of CNS 
abnormalities were age at onset of puberty <6 years (adjusted odds ratio 
[AOR]: 6.7; 95% confidence interval [CI]: 1.5–29), lack of pubic hair at 
diagnosis (AOR: 7.7; 95% CI: 1.8 –33), and estradiol >110 pmol/L         
(AOR: 4.1, 95% CI: 1.0 –17). The identification of girls who have CPP 
and require cerebral imaging seems possible on the basis of validated, 
simple, and reproducible predictors: age and estradiol. 
10. B.M.Taher et al., (32) from endocrine clinic of Jordan 
university hospital evaluated 43 girls and 7 boys with precocious puberty. 
Mean age for the girls with precocious puberty was 4.1 ± 2.5 S.D and for 
boys was 2.4 ± 1.9 S.D. among the girls 21% presented with breast 
development only,9% with pubic hair appearance and enlarged genitalia. 
Organic causes for precocious puberty were detected in 42% of girls and 
in all the boys. Idiopathic precocious puberty was more common among 
girls presenting with breast development only (89%) compared with those 
presenting with multiple signs (50%) and also was more common among 
girls presenting between 6 and 8 years of age(82%) than among those 
presenting <6 years of age (42%). Congenital adrenal hyperplasia was 
diagnosed in four boys and four girls. Hypothyroidism was diagnosed in 
three girls. 
 STUDY JUSTIFICATION 
The advent of newer imaging modalities has led to the 
identification of neurological etiology in a majority of children previously 
diagnosed as having idiopathic central precocious puberty (33).  
Clinicians who deal with CPP have two main concerns: detection 
of CNS abnormalities and short final height. Thus a means of identifying 
the group of girls who have CPP and are at high risk of CNS 
abnormalities is essential. 
Though there are many reports regarding the sexual precocity from 
west, Indian data regarding precocious puberty are limited (23, 24, 25, 
and 30). 
This study was planned to evaluate the etiology, clinical features, 
and endocrine profile and factors predicting neurogenic etiology in 
children with central precocious puberty (CPP) being followed up in a 
tertiary care center. 
  
AIM OF THE STUDY 
1. To evaluate the clinical and endocrine profile of patients with 
precocious puberty followed up in a tertiary care hospital 
2. To identify predictors of central precocious puberty (CPP) that 
reveals central nervous system (CNS) abnormalities in girls with 
CPP. 
MATERLALS AND METHODS 
METHODOLOGY 
STUDY DESIGN : 
Descriptive Study 
STUDY SETTING   : 
Endocrinology Division, ICH and HC, Egmore. 
STUDY PERIOD    : 
October 2009 to September 2011. 
STUDY POPULATION :  
All cases attending endocrinology out-patient and diagnosed as 
premature sexual development. 
CASE DEFINITION : 
Appearance of secondary sexual characteristics in an age that is 
less  8 years in girls and 9 years in boys or the onset of menstruation                                                   
Before 9.5 years in girls. 
MANOEUVRE: 
This study was done in the endocrinology outpatient department of 
Institute of child health Egmore. Retrospective analysis of case records of 
children with precocious puberty under follow up during the study period 
and prospective analysis over a period of 3 years, seventy seven children 
were enrolled in the study through non-probability convenience sampling 
method. Analysis included age of onset, family history, presenting 
features of precocity, features suggestive of central nervous system 
(CNS) involvement, exposure to drugs especially steroids, and features of 
endocrinopathies including hypothyroidism and congenital adrenal 
hyperplasia (CAH). The age at the onset of puberty was defined as the 
age when breast development was first noted by the patient or their 
parents. Other data were the values recorded at the first physical 
examination.   
Clinical features, such as the stage of pubertal development, CNS 
abnormalities and features of endocrine disorders, were analyzed. 
Testicular volume was measured by a Praders orchidometer. Sexual 
maturity was rated according to Tanner's pubertal staging in both boys 
and girls. 
Height was measured with a Harpenden stadiometer and weight 
was recorded using a digital weighing scale and compared with Agarwal 
standard charts, for age and sex matched percentiles (47, 48) and were 
expressed as Z score with respect to chronological age and sex. Body 
weight was expressed as body mass index (BMI) (weight in 
kilograms/height in m
2
) 
Endocrine evaluation included baseline luteinizing hormone (LH), 
follicle stimulating hormone (FSH) and testosterone/estrogen levels in all 
patients. A gonadotropin releasing hormone agonist (GnRH agonist) 
stimulation test was performed in doubtful cases where basal 
gonadotropin levels are inconclusive. LH and FSH levels were estimated 
at 0 hour, 4 hour and 24 hour after injection of 10 μg /kg of GnRH 
agonist intramuscularly (3). Precocious puberty was diagnosed with 
pubertal levels of LH or a ratio of LH: FSH greater than 1, Stimulated LH 
> 10mIu /mL, and LH rises three fold over baseline. Blunted response is 
pathognomonic of peripheral precocious puberty.   Other endocrine 
investigations included thyroid profile, 17-hydroxyprogesterone (170HP) 
(baseline and after adrenocorticotropic hormone [ACTH] stimulation), 
dehydroepiandrosterone (DHEA) and human chorionic gonadotropin 
(HCG) estimations. All hormonal investigations were carried out by 
enzyme immunoassay method.  Bone age (BA) was estimated using the 
radiographic atlas of skeletal development. Ultrasonogram (USG) of the 
abdomen and pelvis was performed in all girls with precocious puberty 
and computerized tomography (CT) scan and Magnetic resonance 
imaging (MRI) of the brain was performed in children as and when 
indicated. 
STATISTICAL ANALYSIS 
Datas were entered using Microsoft corp. excel and analysed using 
SPSS (statistical package for social sciences) version 16 for windows. 
Statistical analysis included estimation of mean and standard deviation 
for clinical auxological and endocrine parameters. Differences between 
two continuous variables were estimated by independent t-test.  P values 
less than 0.05 were considered significant. 
OBSERVATIONS 
Out of 77 children with precocious puberty, 76.6% (n=59) were 
girls and 23.4 %( n=18) were boys (figure 1).  
AGE OF ONSET 
Mean age of onset for girls and boys under the study were 5.8 ± 2.1 
and 7.43 ± 1.4 respectively. Majority of the children in the study 
population were in the age category of 6-7years (48% girls and 52% 
boys). Age of onset was similar in girls and boys with CPP and PPP 
(Table 2 and 3). Girls with neurogenic CPP had earlier age of onset than 
those with idiopathic CPP, while the difference in boys was not 
significant (Table 5). Two girls with hypothalamic hamartoma had the 
lowest age of onset 2 years and 2.6 years respectively. Girls with 
premature thelarche had a relatively later age of onset compared to those 
with CPP (Table 6).  
CLINICAL FEATURES 
Breast enlargement was the commonest presenting feature in 
81.4% girls (n=48) and cyclical vaginal bleeding was the presenting 
complaint in 18.6% girls (n=11). Appearance of pubic hair was present in 
all girls with peripheral precocity 5.1% (n=3) and in 71.8% of girls 
(n=28) with central precocious puberty. Family history of early menarche 
was present in 8.5% girls (n=5) and all of them presented with idiopathic 
CPP.  All boys with central precocity (n=13) had testicular and penile 
enlargement while pubarche was present in 27% (n=5).Testicular volume 
was prepubertal in all the 4 boys with non- classical 21 hydroxylase 
deficiency. Involvement of central nervous system like seizures and 
mental retardation, was present in 28.5% girls (n=2) and 28.5 % boys 
(n=2) with neurogenic CPP. 
Table :  2 Comparison  of  central  and peripheral precocious 
puberty in boys 
No 
Clinical and 
auxological 
parameters 
CPP 
(mean±S.D) 
PPP 
(mean±S.D) 
T 
Value 
P 
Value 
1. Number 13 5 - - 
2. 
Age of onset 
(yr) 
5.6± 0.9 7.3 ±0.5 3.264 0.005 
3. Height SD 1.9±0.2 1.4±0.2 3.643 0.002 
4. 
Bone age-
chronological 
age(yr) 
4.1±1.1 3.3± 0.6 1.491 0.080 
 
 
Table : 3  Comparison  of  central  and  peripheral precocious 
puberty in girls 
No. 
Clinical and 
auxological 
parameters 
CPP 
(mean±S.D) 
PPP 
(mean±S.D) 
T 
Value 
P Value 
1. Number 39 3 - - 
2. 
Age of onset 
(yr) 
5.8 ± 0.8 6.2 ±0.8 0.735 0.467 
3. Height SD 1.7±0.3 1.3±0.1 2.106 0.042 
4. 
Bone age-
chronological 
age(yr) 
3.4±0.8 3.1± 0.5 0.620 0.538 
 
Auxological parameters: 
10 out of 14 children with neurogenic CPP had a height above the 
97
th 
centile, and in the rest of the 4 children it was between the 75
th
 and 
97
th
 centile. Height was measured in 38 children with idiopathic CPP, of 
which 24 children fell between the 75
th
 and 97
th
 centile and 14 children 
were above the 97
th
 centile. The height of 15 girls with premature 
thelarche fell between the 3
rd
 and 25
th
 centile, and in 8 girls with PPP 
height was between the 25
th
 and 50
th
 centile. In 2 girls with 
hypothyroidism height was less than 3
rd
 centile. 
In 25 girls with CPP, BMI was more than 85
th
 centile (overweight), 
in 7 girls with CPP and 2 girls with hypothyroidism BMI was above the 
95
th
 centile (obesity). In 7 girls with CPP and in 3 girls with PPP, BMI 
was between the 75
th
 and 85
th
 centile. 
In 13 boys with CPP, BMI was between the 10 and 25
th 
centile and 
in 3 boys with CPP and 5 boys with PPP, BMI was between the 25
th
 and 
50
th
 centile.  
42.5% Girls with precocious puberty were overweight (n=25) and 
15.2% (n=9) were obese, unlike the boys who were neither overweight 
nor obese. 
BONE AGE EVALUATION 
Bone age was advanced in all children with precocious puberty 
except in 2 girls in whom hypothyroidism was the underlying aetiology. 
They presented with a markedly retarded bone age (Bone age – 
chronological age = -2). Advanced bone age was most pronounced 
among all 4 boys with non-classical 21 hydroxylase deficiency. Boys 
with central precocity had greater bone age advancement compared to 
boys with peripheral precocity (Table 2). No significant difference in 
bone age advancement was seen in girls with central precocity compared 
with peripheral precocity (table 3). However advanced bone age was 
statistically significant in boys and girls with idiopathic CPP compared 
with neurogenic CPP (table 4 and 5).  
 Table : 4  Comparison  of  idiopathic  and  neurogenic  precocious 
puberty in boys 
No 
Clinical and 
endocrine 
profile 
Idiopathic 
CPP 
(Mean±S.D) 
Neurogenic 
CPP 
(Mean±S.D) 
T-value 
P-
value 
1. Number 6 7 - - 
2 
Age of onset 
(yr) 
5.7±0.9 5.6±1.0 0.242 0.813 
3 Height S.D 2.0±0.1 1.7±0.09 4.228 0.001 
4 BA-CA (yr) 3.1±0.4 5.0±0.6 6.566 <0.001 
5 
Serum. 
Testosterone 
(ng/dL) 
39.8±8.1 39.6±7.3 0.923 0.968 
6 
Basal 
LH(mIu/ml) 
3.9±0.7 5.0±0.7 2.682 0.021 
7 
Basal 
FSH(mIu/ml) 
2.6±0.2 3.5±0.6 3.214 0.008 
8 Basal LH: FSH 1.5±0.4 1.4±0.1 0.539 0.600 
9 
Peak 
LH(mIu/ml) 
27.7±2.8 42.3±3.6 7.897 <0.001 
10 
Peak 
FSH(mIu/ml) 
14.5±1.0 13.2±1.5 1.736 0.110 
11 Peak LH: FSH 1.9±0.1 3.2±0.4 6.554 <0.001 
 
ENDOCRINE INVESTIGATIONS 
Thyroid function test was done in all the 77 children enrolled in the 
study. Elevated TSH (>5 μIU/ml) and decreased T4 (<51 nmol/L) was 
observed in 3.4% girls (n=2). Girls with neurogenic CPP had higher 
levels of baseline LH, FSH and LH: FSH ratio than those with idiopathic 
CPP (table 5). The difference was accentuated by GnRH stimulation. 
Boys with neurogenic CPP had higher levels of baseline LH, FSH, peak 
LH and peak LH: FSH ratio compared to those with idiopathic CPP (table 
4). Predominant FSH response was seen in all girls diagnosed as isolated 
premature thelarche. Though basal FSH was indiscriminatory between 
premature thelarche and central precocious puberty, a significant 
difference was observed in FSH response after GnRH stimulation (table 
6).  
Table : 5  Comparison  of  idiopathic  and  neurogenic  precocious 
puberty in girls 
no 
Clinical and 
endocrine 
profile 
Idiopathic 
CPP 
(Mean±S.D) 
Neurogenic 
CPP 
(Mean±S.D) 
T-value P-value 
1. Number 32 7 - - 
2 
Age of onset 
(yr) 
6.0±0.7 4.8±0.3 4.476 <0.001 
3 Height S.D 1.6±0.2 1.9±0.2 2.616 0.013 
4 BA-CA (yr) 3.1±0.7 4.5±0.4 5.016 <0.001 
5 
Serum. Estradiol 
(pg/mL) 
6.6±0.9 13.3±1.0 16.471 <0.001 
6 
Basal 
LH(mIu/ml) 
3.9±0.6 5.4±0.6 5.634 <0.001 
7 
Basal 
FSH(mIu/ml) 
2.7±0.3 4.3±0.6 6.357 <0.001 
8 Basal LH: FSH 1.4±0.2 1.2±0.1 1.859 0.071 
9 
Peak 
LH(mIu/ml) 
32.6±5.1 42.1±6.9 4.188 <0.001 
10 
Peak 
FSH(mIu/ml) 
14.67±1.01 14.9±2.5 0.244 0.815 
11 Peak LH: FSH 2.2±0.3 2.5±0.3 1.813 0.078 
 
Serum 17 β estradiol estimation was done in all 59 girls with 
precocious puberty. Elevated estradiol levels (> 10 pg / mL) were seen in 
all 39 girls with central precocity. Significant elevation was seen in girls 
with neurogenic CPP compared with idiopathic CPP and premature 
thelarche (table5, 6). 
Table : 6  Comparison  of  central  precocious  puberty and 
premature thelarche in girls 
No 
Clinical and 
endocrine 
profile 
CPP 
(Mean±S.D) 
Premature 
thelarche 
(Mean±S.D) 
T-value P-value 
1. Number 39 15 - - 
2 
Age of onset 
(yr) 
5.8±0.8 7.0±0.2 8.466 <0.001 
3 Height S.D 1.7±0.3 0.7±0.2 10.931 <0.001 
4 BA-CA (yr) 3.4±0.8 0.5±0.4 11.949 <0.001 
5 
Serum estradiol 
(pg/mL) 
7.8±2.7 5.5±1.6 2.984 0.004 
6 
Basal 
LH(mIu/ml) 
4.2±0.8 1.8±0.4 13.283 <0.001 
7 
Basal 
FSH(mIu/ml) 
2.9±0.7 3.0±0.5 0.114 0.910 
8 Basal LH: FSH 1.4±0.2 0.6±0.1 10.948 <0.001 
9 
Peak 
LH(mIu/ml) 
34.3±6.5 3.8±0.6 28.901 <0.001 
10 
Peak 
FSH(mIu/ml) 
14.7±1.3 7.8±0.4 28.000 0.001 
11 Peak LH: FSH 2.2±0.3 0.4±0.07 27.317 <0.001 
Serum testosterone levels were estimated in all the 18 boys with 
premature sexual development. Levels more than 25 ng /dL was present 
in all 13 boys with central precocity. No significant difference in serum 
testosterone levels was observed in boys with idiopathic and neurogenic 
CPP (table 4). A grossly elevated serum testosterone level (410 ng /dL) 
was present in 1 boy with testotoxicosis. 
ULTRASONOGRAM OF PELVIS 
Ultrasonogram (USG) of pelvis for utero-ovarian evaluation 
demonstrated enlarged uterus  (> 3.5 cm) and ovaries in 66% of the girls 
(n=39) (All the 39 girls were diagnosed as CPP). 27% of the girls (n=16) 
with central precocity had multiple small ovarian cysts. Endometrial 
thickness of more than 3mm was present in 87% of the girls (n=34) with 
central precocity. 
NEUROIMAGING 
CT brain was done in 10 girls and 6 boys with central precocity. 
Craniopharyngioma was detected in 1 girl. MRI brain was done in 29 
girls and 7 boys. Neurotuberculosis in 5.1% girls (n=2), empty sella in 
5.1% girls (n=2) and hypothalamic hamartoma in 5.1% girls (n=2) were 
the findings revealed by MRI in girls with central precocious puberty. 
Supracellar arachnoid cyst in 15.3% boys (n=2), hypothalamic 
hamartoma in 23% boys (n=3) and neurotuberculosis in 15.3% boys 
(n=2) were the abnormalities detected by MRI in boys with central 
etiology. Neuroimaging revealed abnormalities in 11.9% girls (n=7) and 
38.9% boys (n=7). 
PREDICTORS OF NEUROGENIC ETIOLOGY IN CHILDREN 
WITH CENTRAL PRECOCIOUS PUBERTY : 
 No significant  difference in age of onset was observed between 
boys with idiopathic and neurogenic CPP. 
 Advanced bone age, elevated basal LH, basal FSH, Peak LH and 
Peak LH : FSH ratio were significantly higher in boys with neurogenic 
CPP (Table 4). 
 Compared to idiopathic CPP, girls with neurogenic CPP had an 
earlier age of onset, advanced bone age and height S.P. scores (Table 5). 
 Elevated serum estradiol, basal LH, basal FSH, Peak LH were 
significantly higher in girls with neurogenic CPP (Table 5). 
Table : 7 Etiology of precocious puberty 
No. Category Girls Boys Total 
1. Idiopathic central precocity 
32 
(54.2%) 
6 
(33.3%) 
38 
(49.4%) 
2. 
Neurogenic central 
precocity 
7   
(11.9%) 
7 
(38.9%) 
14 
(18.2%) 
a. Neurotuberculosis 2 2  
b. 
Hypothalamic 
hamartoma 
2 3 
c. Craniopharyngioma 1 - 
d. Empty sella syndrome 2 - 
e. 
Supracellar arachnoid 
cyst 
- 2 
3. Premature thelarche 15(25.4%) - 15(19.5%) 
4. Peripheral precocity 3(5.1%) 5(27.8%) 8(10.4%) 
 
a. Ovarian cyst 2 -  
b. 
McCune-Albright 
syndrome 
1 - 
c. 
Non-classical 21 
hydroxylase deficiency 
- 4 
d. 
Male-limited precocious 
puberty (Testotoxicosis) 
- 1 
5. Hypothyroidism 2(3.4%)  2(2.6%) 
DIAGNOSIS 
Based on clinical and endocrine evaluation the study population 
was categorized into three major groups (table 7) (i) Central precocious 
puberty (ii) Peripheral precocious puberty and (iii) Isolated normal 
variants. 
The most common etiology among our study population (figure 2) 
was central precocious puberty seen in 66% girls (n=39) and 72.2% boys 
(n=13) respectively. Out of the above 33.3% boys (n=6) and 54.2% girls 
(n=32) were diagnosed with idiopathic central precocious puberty. 38.9% 
boys (n=7) and 11.9% girls (n=7) were diagnosed with neurogenic central 
precocious puberty. 
Among the central causes (figure 3) neurotuberculosis was 
identified as the etiology in 11.1% boys (n=2) and in 3.3% girls (n=2). 
Hypothalamic hamartoma in 16.6% boys (n=3) and 3.3% girls (n=2) were 
the cause for central precocity. In 11.1% boys (n=2) arachnoid cyst was 
identified as the etiology and empty sella was the etiology in 3.3% girls 
(n=2).  
Hypothyroidism was present in 3.4% girls (n=2) and isolated 
premature thelarche in 25.4% girls (n=15). No child with isolated 
premature pubarche or premature menarche has been reported in our 
study. 
Peripheral precocious puberty (figure 4) was identified as the 
etiology in 27.8% boys (n=5) and 5.1% girls (n=3). Among the peripheral 
causes in girls ovarian cyst in 3.3% (n=2) and McCune-Albright 
syndrome in 1.7% (n=1) were identified as the etiology. Among boys     
non-classical 21 hydroxylase deficiency was present in 22.2% (n=4) and 
testotoxicosis in 5.5% (n=1). 
Figure 1  : Sex distribution of study population 
 
Fig 2: Etiology of precocious puberty 
 
                     
 Fig 3: Etiology of neurogenic central precocious puberty 
 
Fig 4: Etiology of peripheral precocious puberty 
 
DISCUSSION 
Wide variation exists in the clinical spectrum of premature sexual 
developments and its etiology is multifactorial.  Precocious puberty is 
present more commonly in girls than boys (female to male ratio 5-10:1 
approximately). (23-32) In our study 77%  of children were girls and 23% 
were boys, therefore female to male ratio was 3.5:1. In studies by Meena 
Desai et al (23), Bajpai et al (30), Chemaitilly et al (26), and Taher et al 
(32), 72.5%, 81%, 89%, 85% and 86 %, of patients were girls 
respectively.  
Our data demonstrate that central precocious puberty was present 
more commonly in girls, seen in 51% (39 / 77) than boys 17% (13/77). 
The majority of girls with central precocious puberty (82 %) had 
idiopathic CPP where no etiology has been established (idiopathic CPP to 
neurogenic CPP ratio, 5:1), whereas a neurogenic cause was identified in 
54% of boys (idiopathic CPP to neurogenic CPP ratio, 1:1). This further 
signifies the fact that CPP is uncommon in boys, but when it does occur it 
is usually due to an underlying neurological cause (39). The incidence of 
neurogenic CPP in the present study 18 % is comparable to that of other 
reports from our country (23, 25 and 30). This increased incidence of 
neurogenic CPP compared to studies done earlier may be due to an 
improvement in radiological investigations (24, 40). Recent studies have 
shown an increase in the incidence of neurogenic CPP (29, 30). Our 
findings were consistent with Bajpai et al, where 67.5% of female 
patients had CPP, 80% of which were idiopathic CPP. Furthermore, 56% 
of boys with CPP had neurogenic cause and 44 % had Idiopathic CPP. 
Findings of the most studies reiterate the increased incidence of 
idiopathic central precocious puberty in girls and neurogenic central 
precocious puberty in boys. The etiology of idiopathic precocious puberty 
in girls is unknown. This is possibly explained by early reactivation of 
hypothalamic-pituitary- gonadal axis in girls in comparison to boys (41). 
Hypothalamic hamartoma was the commonest cause of neurogenic 
CPP (35.7%, 5/14) in our study (three girls and two boys). Gelastic 
seizures or laughing spells is the commonest presentation; none of our 
children with hypothalamic hamartoma manifested it. LH-releasing 
hormone containing fibers have been observed within hamartoma tissues 
in patients with CPP. These patients presented at an early age, as in other 
reports (42). These patients respond to GnRH analog therapy and surgical 
correction is not required (42, 43). Neurotuberculosis was the second 
most common cause of neurogenic CPP in this series, reflecting a greater 
prevalence of tuberculosis in our country. We report two girls who had all 
the manifestations of central precocious puberty but empty sella was the 
only finding on MRI brain. Empty sella syndrome in association with 
CPP has been reported (44), but whether it plays a role in causing CPP is 
debatable. Supracellar arachnoid cyst was reported in two boys with 
features of central precocious puberty and headache was the only 
presenting complaint. 
According to the present study, in 5.1% of girls and 27.8% of boys 
peripheral causes were identified as the etiology of precocious puberty. 
Adrenal causes, Non-classic 21-hydroxylase deficiency are the 
commonest cause (80%, 4/5) of PPP in boys, as reported by Desai et al 
(23), Taher et al (32), and Bajpai et al (30).  These boys presents with 
enlarged penis and early appearance of pubic hair with prepubertal testes 
in the absence of salt wasting. 170HP levels are elevated and an ACTH 
stimulation test is required for definitive diagnosis. One boy presented 
with all the features of central precocious puberty with grossly elevated 
basal testosterone. However response to GnRH stimulation is prepubertal 
and testicular biopsy revealed leydig cell hyperplasia confirming 
testotoxicosis.  
PPP in girls is usually secondary to follicular ovarian cysts. 
Follicular cysts secrete estrogens that cause mammary development or 
even non-cyclical vaginal bleeding. They can be recurrent, causing a 
transient rise of estradiol levels. Larger follicular cysts can present torsion 
of the pedicle and infarction, requiring surgical intervention.   Girls with 
CPP may have multiple ovarian cysts on USG, as in most post pubertal 
girls. These should not be confused with estrogenic ovarian cysts. The 
cysts resolve spontaneously in most patients as the puberty regresses (45). 
Clinical diagnosis of McCune-Albright syndrome was diagnosed in one 
girl with typical café au lait macules, polyostotic fibrous dysplasia and 
GnRH- independent precocious puberty. She had elevated estradiol, 
multicystic ovaries on USG of pelvis with low basal LH & pre-pubertal 
response to GnRH stimulation.   
Long-standing untreated primary hypothyroidism has been 
associated with precocious puberty. This is explained by an increase in 
the levels of prolactin and FSH and FSH-like activity of the alpha subunit 
of TSH (46). Two girls present with delayed bone age, clinical features of 
hypothyroidism, significantly elevated TSH (>100 mIu/mL), normal 
gonadotropin levels and elevated estradiol levels. Thyroxine 
supplementation in these girls leads to normalization of thyroid status and 
disappearance of secondary sexual characteristics. 
In our study incomplete variant was considered as the second 
common cause (25.4%) of precocious puberty in girls, with dominancy of 
premature thelarche. None of the children were reported with premature 
pubarche in this series. Desai et al (23) study showed 46 % of girls with 
precocious puberty had normal variant and 35 % of them had premature 
thelarche. In comparable with our finding, supported by the conclusions 
of Taher et al (32) and Bajpai et al (30) studies, incomplete normal 
variant was the cause of precocious puberty in 21% and 25.5% of patients 
respectively.  
Girls with neurogenic CPP had an earlier age of onset than those 
with idiopathic CPP, a finding that is similar to that in other studies (23, 
39, and 40). In boys, the age of onset of neurogenic CPP was not different 
from that of idiopathic CPP. This emphasizes the need for careful CNS 
imaging in boys with precocious puberty. Current guidelines recommend 
that CNS imaging is not required in girls after 6 years as the incidence of 
neurogenic CPP is very low after this age (18). Studies have, however, 
indicated that neurogenic etiology may be present in girls with pubertal 
onset between 6 and 8 years of age 
The LWPES’s recommendations (12) were formulated to identify 
girls who have CPP and need evaluation for risk of both CNS 
abnormalities and short final height. Their conclusions were derived 
mainly from a study in which the cause of precocious puberty was not 
assessed. Those new recommendations raised some concerns. Given that 
they were designed to apply to American girls, we found that in the 
present study, three girls older than 6 years had neurogenic CPP. In a 
multicentric Italian study, 16% of girls older than 7 years with precocious 
puberty had neurogenic CPP (13) .These findings indicate the need for 
CNS imaging in these girls in contrast to the current recommendations. 
The need for CNS imaging should therefore be individualized according 
to the age at onset, rate of progression and neurological features. Larger 
studies may be required to revise these guidelines. 
14 girls with idiopathic CPP (14 /32, 44%) presented after the age 
of 6 years. This, coupled with recent findings that puberty is occurring 
earlier in girls, raises the question whether the current age criteria for the 
diagnosis of precocious puberty are inappropriately high. The present 
study was conducted in a tertiary referral center and thus has the 
limitation of selection bias in regard to physiological variation, which is 
less likely to be referred. Recommendations for lowering the age limit for 
the definition of precocious puberty have been made but have not yet 
been universally accepted (12). These recommendations are based on 
western studies and do not take into account factors such as nutrition, 
obesity and socio-economic status. Age criteria for precocious puberty in 
developing countries require population-based studies that are so far 
scanty. 
Features of CNS involvement, such as seizures, mental retardation, 
hydrocephalus and focal neurological deficits, favor neurogenic CPP. 
Patients with neurogenic CPP have advanced bone age which is also the 
case in the present study early age of onset.  Levels of estradiol, basal  
LH, basal FSH and Peak LH  were higher in neurogenic CPP compared to 
idiopathic CPP in girls. Our findings were comparable with Cacciari et al 
(35) and Bajpai et al (30), where early age of onset in girls, clinical 
features of CNS involvement, and elevated basal and stimulated LH,FSH  
levels and LH: FSH ratio were the predictors of neurogenic CPP. 
However study by Martin chalumeau et al (31), revealed entirely different 
predictors like, age at onset of puberty less than 6 years, lack of pubic 
hair at diagnosis, and estradiol more than 110 pmol/L. This can be 
explained by difference in statistical analysis, selection bias and number 
of children recruited for the study.  
CONCLUSION 
1. Precocious puberty was more common among girls. The most 
common etiology of precocious puberty in girls was idiopathic 
CPP (54.2%) followed by premature thelarche (25.4%).  
2.  Most common etiology of precocious puberty in boys was 
neurogenic CPP (38.9%) followed by peripheral precocious 
puberty due to CAH, non – classical 21hydroxylase deficiency 
(23%). 
3. Central precocious puberty in girls is usually idiopathic, but in 
boys is more likely to be the result of a demonstrable CNS lesion. 
This conclusion made it mandatory for neuro imaging (either CT or 
MRI) in boys with CPP. 
4. Neurogenic CPP was present in three girls with age of onset after 6 
years, indicating the need for CNS imaging in girls with age of 
onset after 6 years in contrary to the current recommendations. 
5. Predictors of central nervous system abnormalities in girls with 
neurogenic CPP were early age of onset, advanced bone age, 
elevated levels of serum estradiol, basal LH, basal FSH and Peak 
LH.. 
SUMMARY 
1. All children presenting with precocious puberty require a detailed 
history and clinical evaluation before commencing investigations 
and treatment.  
2. Normal pubertal variants like premature thelarche require only 
reassurance and periodic follow-up. The pediatrician therefore 
should be adept in differentiating normal pubertal variants from 
pathological precocious puberty.  
3.  Unnecessary investigations should be avoided if features of 
precocious puberty are inconsistent or not clearly evident and the 
patient must be reviewed after a few months for reassessment. 
4.  All forms of PPP should be managed according to the etiology, 
predicted adult height and psychological concerns. 
5.  Suppression of CPP with GnRH analogues should be considered 
when there is significant compromise to adult stature and 
behavioral issues. 
6.  Urgent need for population-based studies including biological 
work-up and brain imaging to exclude premature thelarche, 
primary gonadal precocious puberty, and CPP revealing CNS 
abnormalities. 
7.  Predictors for short final height and/or CNS abnormalities, 
identified by rigorous statistical analysis, need to be established. 
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ANNEXURE 1 
PROFORMA 
Serial No 
Name                 :  
Age:  
Sex 
Address              : 
Age of onset of Presenting Complaints     : 
Presenting Complaints         : 
Past history of CNS involvement                       : 
H/O drug intake (exogenous steroids)                 : 
Family history of early menarche                     : 
CLINICAL EXAMINATION                                                              
Goiter                                                   : 
Features of hypothyroidism                  : 
Axillary Hair                                         : 
Breast Development (Tanner Staging) : 
Galactorrhea                                          : 
Pubic Hair (Tanner Staging)                 : 
Clitoromegaly                                        : 
Stretch penile length (cm)                     : 
Testicular Volume (Tanner Staging)     : 
Menstruation     :       
ANTHRAPOMETRY  
Weight      : 
Height      : 
BMI      :     
INVESTIGATIONS 
RADIOLOGICAL 
X-ray for Bone Age                         : 
USG Abdomen                                 :       
Pelvis                                                : 
C.T. Scan Brain                                 : 
MRI Brain                                          : 
HORMONAL (BLOOD) 
T4          : 
TSH      : 
GNRH 
STIMULATION 
BASAL PEAK 
LH   
FSH   
 
17 β ESTRADIOL    : 
TESTOSTERONE    : 
17-OHP     : 
DHEA / DHEAS    : 
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